Exclusive Summary

• As a WHO Essential Medicine with no patent barriers, Propofol is a rigid-demand, first-line IV anesthetic for over 300 million major surgeries and tens of millions of endoscopies globally per year.
• In light of frequent global supply shortages of Propofol, the mature Chinese supply chain ensures stable and continuous massive supply, acting as a perfect target for overseas pharmas seeking supply chain diversification.
• Leveraging economies of scale from Chinese manufacturing, this product offers extraordinary cost advantages in national tenders and public hospital procurement, preserving lucrative margin spaces for overseas distributors.
• The 20ml:0.2g (1%) strength is the most universally adopted mainstream specification, which, combined with ready-to-file international CTD dossiers, enables rapid local registration and market penetration.